Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + NALIRIFOX
- Development stage
- Unknown
- Lead developer
- University of Colorado Cancer Center
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal, Intravenous
01
Overview
This combination therapy involves the administration of intraperitoneal (IP) paclitaxel alongside the systemic NALIRIFOX regimen, which consists of liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin. Developed and evaluated by the University of Colorado, Denver, this specific protocol is designed to treat pancreatic ductal adenocarcinoma (PDAC) that has metastasized to the peritoneum (peritoneal carcinomatosis). The rationale for the intraperitoneal administration of paclitaxel is to achieve high local concentrations of the cytotoxic agent within the abdominal cavity to directly target peritoneal surface malignancies while minimizing systemic side effects. Paclitaxel acts as a microtubule stabilizer to inhibit mitosis, while the NALIRIFOX components provide multi-targeted systemic effects through DNA alkylation, topoisomerase I inhibition, and antimetabolite activity.
- Brand names
- Onivyde
- Other names
- IP paclitaxel + NALIRIFOXIntraperitoneal Paclitaxel + NALIRIFOX
02
Targets
TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)DNATOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on paclitaxel + NALIRIFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + NALIRIFOX.